Alnylam: KARDIA-1 Phase 2 Dose-Ranging Study Of Zilebesiran Meets Primary Endpoint
(RTTNews) - RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Thursday positive topline results from the KARDIA-1 Phase 2 study of zilebesiran.
zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen or AGT in development for the treatment of hypertension in patients at high cardiovascular risk.
The KARDIA-1 Phase 2 trial is a randomized, double-blind, placebo-controlled, multi-center global dose-ranging study designed to evaluate the efficacy and safety of zilebesiran as monotherapy in adults with mild-to-moderate hypertension.